In early July, President Biden signed into law the National Plan to End Parkinson's Act. Seeing this bipartisan legislation become law is heartening, as it will bolster efforts to find new treatments and ultimately cure Parkinson's. 23andMe launched our Parkinson's Research effort 15 years ago, leveraging our unique research model to aid in the fight against this disease. More than 33,000 people with Parkinson's are now part of our Parkinson's Research community. That community and the millions of 23andMe customers who have consented to participate in our research make this work possible. Together, we've published over two dozen papers. Collaborating with the Michael J. Fox Foundation and the Parkinson's Foundation, among others, we hope to make progress towards our goal of ending Parkinson’s.
About us
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.
- Website
-
https://www.23andme.com
External link for 23andMe
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Sunnyvale, California
- Type
- Public Company
- Specialties
- genetic research, consumer genetics, direct-to-consumer genetic testing, telehealth, healthcare, wellness, therapeutics, and drug discovery
Locations
-
Primary
Get directions
223 N Mathilda Ave
Sunnyvale, California 94086, US
-
Get directions
349 Oyster Point Blvd
South San Francisco, CA 94080, US
Employees at 23andMe
Updates
-
We’re looking for a Corporate Counsel to join our legal team! In this role, you’ll advise on a broad range of corporate, governance, securities law, commercial, strategic transactions, and other matters. Come join our Gene Pool! https://lnkd.in/gUXMKaYj
-
You know your calendar age, but do you know your biological age? Our new feature analyzes key biomarkers, from blood tests included in 23andMe+ Total Health, that reflect the condition of major body systems and organs. Part of 23andMe+ Total Health. Our new Biological Age feature helps you monitor how your body is aging physiologically so you can change the trajectory of your health. Learn more: https://23and.me/4eHFuyH The information provided in the Biological Age feature is intended for informational use only, has not been reviewed by a clinician, and is not intended to provide medical advice. Talk to a healthcare professional if you have any concerns or before making any major lifestyle changes.
-
-
We're excited to announce a strategic collaboration with Nightingale Health to offer more services to our subscribers. 23andMe will pilot Nightingale’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe’s established personal genetics products. More below and in our press release here: https://lnkd.in/grn_ty74
23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel Nightingale Health and 23andMe today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale’s Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe’s established personal genetics products. “We are truly impressed with Nightingale Health’s capabilities in blood biomarker testing. Their work with public biobank projects and resulting publications have previewed the exciting potential for metabolomics in prediction. We believe this collaboration will ultimately help our customers lead longer, healthier lives,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are enthusiastic about long-term opportunities that combine the power of our technologies.” “This collaboration enables a globally unique feature set for 23andMe’s consumer health services. Together, we can help customers track and improve their health with regular blood testing using Nightingale Health’s technology,” said Teemu Suna, CEO and Founder of Nightingale Health. “This marks an important step in the execution of Nightingale Health’s strategy, as it announces an important partnership providing access to the consumer health market.” Read more: https://lnkd.in/eWnVusH4
-
More thoughts on the new era of genetic medicine from our CEO and co-founder Anne Wojcicki last weekend at #AspenHealth. 🧬 #femalefounder #geneticmedicine #preventativehealthcare
-
-
You know your calendar age, but do you know your biological age? Our new feature analyzes key biomarkers, from blood tests included in 23andMe+ Total Health, that reflect the condition of major body systems and organs. Part of 23andMe+ Total Health. Our new Biological Age feature* helps you monitor how your body is aging physiologically so you can change the trajectory of your health. Learn more: https://lnkd.in/ghfSzUq5 *The information provided in the Biological Age feature is intended for informational use only, has not been reviewed by a clinician, and is not intended to provide medical advice. Talk to a healthcare professional if you have any concerns or before making any major lifestyle changes.
-
-
“The fact that the LRRK2 G2019S variant is found in North African Arabs, Ashkenazi Jews, Sephardic Jews as well as populations in Latin America and the Caribbean is a story of our shared genetic roots,” said Lucy Norcliffe-Kaufmann, Ph.D., Principal Scientist with 23andMe’s Parkinson’s Disease Research program. Learn more about the study: https://23and.me/3yNCrEG
The Natural History of a Genetic Variant Associated with Parkinson's Disease
blog.23andme.com
-
A new study published in Nature Genetics identified more than 160 genetic associations for restless leg syndrome. The genetic findings also point researchers to possible drug targets for treating the condition. Curious how restless leg syndrome might impact your health? Learn more on our blog: https://23and.me/3VSILUu
The Genetics of Restless Leg Syndrome
blog.23andme.com
-
Great panel today at Aspen Ideas discussing how genetic data is transforming cancer and other diseases with Anne Wojcicki and other #WomenInSTEM! 🧬
-
-
We’re looking for a Social Expert & Content Creator to join our brand team! This is a Senior Manager position that will build and create content for 23andMe and Lemonaid Health social media channels. https://lnkd.in/grvi4tcW
Social Expert & Content Creator (Senior Manager) – 23andMe Careers
23andme.com